Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645586
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic StrokeBeijing Tiantan HospitalNot Yet RecruitingPhase 3
NCT07645586Not Yet Recruiting
Phase 3
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After A...Beijing Tiantan Hospital
NCT07644390
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort StudySixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
NCT07644390Completed
—
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal...Sixth Affiliated Hospital...
NCT07644351
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia PatientsNovartis PharmaceuticalsCompleted
NCT07644351Completed
—
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lym...Novartis Pharmaceuticals
NCT07646418
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International UniversityRecruitingNot Applicable
NCT07646418Recruiting
Not Applicable
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International Univ...
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07645365
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialysis UnitAntalya Health Sciences UniversityCompleted
NCT07645365Completed
—
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialy...Antalya Health Sciences U...
NCT07643766
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisEnveda TherapeuticsNot Yet RecruitingPhase 2
NCT07643766Not Yet Recruiting
Phase 2
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in...Enveda Therapeutics
NCT07645872
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.EDAP TMS S.A.Recruiting
NCT07645872Recruiting
—
Clinical Data Collection of Patients Treated With High Intensity Focused Ultraso...EDAP TMS S.A.
NCT07644026
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet Recruiting
NCT07644026Not Yet Recruiting
—
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology &...
NCT07644988
Comparing Two Muscle Relaxation Techniques for Neck PainUniversity of FaisalabadActive Not RecruitingNot Applicable
NCT07644988Active Not Recruiting
Not Applicable
Comparing Two Muscle Relaxation Techniques for Neck PainUniversity of Faisalabad
NCT07643974
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research InstituteNot Yet RecruitingEarly Phase 1
NCT07643974Not Yet Recruiting
Early Phase 1
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research I...
NCT07646587
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants With Moderate - Severe COPDWindward BioRecruitingPhase 2
NCT07646587Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants...Windward Bio
NCT07644754
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory MetastasesLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07644754Not Yet Recruiting
Not Applicable
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level...Ludwig-Maximilians - Univ...
NCT07645131
Development of a Mobile Health Intervention to Support Functioning of Veterans With Substance Use DisordersVA Office of Research and DevelopmentNot Yet RecruitingNot Applicable
NCT07645131Not Yet Recruiting
Not Applicable
Development of a Mobile Health Intervention to Support Functioning of Veterans W...VA Office of Research and...
NCT07646535
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismShenzhen Salubris Pharmaceuticals Co., Ltd.Not Yet RecruitingPhase 2
NCT07646535Not Yet Recruiting
Phase 2
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses i...Shenzhen Salubris Pharmac...
NCT07645859
Comparison of High-Intensity Interval Training With Moderate-Intensity Continuous Training in Chronic Non-Specific Low Back Pain PatientsDow University of Health SciencesRecruitingNot Applicable
NCT07645859Recruiting
Not Applicable
Comparison of High-Intensity Interval Training With Moderate-Intensity Continuou...Dow University of Health...
NCT07646028
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLCNot Yet RecruitingPhase 1
NCT07646028Not Yet Recruiting
Phase 1
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLC
NCT07644767
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty LtdNot Yet RecruitingPhase 2
NCT07644767Not Yet Recruiting
Phase 2
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty Lt...
NCT07645430
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.Benha UniversityCompletedNot Applicable
NCT07645430Completed
Not Applicable
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and...Benha University
Result Breakdown
Not yet recruiting9 (45%)
Completed5 (25%)
Recruiting4 (20%)
Active, not recruiting2 (10%)
not_applicable8 (40%)
Not Specified5 (25%)
Phase 24 (20%)
Phase 31 (5%)
Early Phase 11 (5%)
Phase 11 (5%)